BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OKN4395 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OKN4395\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06789172-2653@assetmemo.bio
DTSTAMP:20261121T005652Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:OKN4395: Phase 1 readout est. (NCT06789172)
DESCRIPTION:OKN4395\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phase
  1\, First-in-human Study of OKN4395 and Pembrolizumab in Patients With So
 lid Tumors\nEstimated primary completion: July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/okn4395#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06789172
URL:https://assetmemo.bio/drug/okn4395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
